Naramig (Naratriptan)

Naratriptan, the active ingredient in Naramig, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for systemic use. It is indicated for the acute treatment of migraine attacks in adult patients, providing relief from headache and associated symptoms such as nausea, photophobia, and phonophobia.

GNH USA supplies Naramig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products that meet European Union regulatory standards and supporting reliable supply chains.

Naratriptan is a triptan class medication used to treat migraine, a neurovascular headache disorder.

Migraine: provides acute relief of headache pain and associated symptoms such as nausea, photophobia, and phonophobia.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient feeling of light‑headedness. - Fatigue: unusual tiredness after dosing. - Dry mouth: reduced salivation. - Tingling sensations: paresthesia in extremities. - Chest discomfort: mild pressure or tightness.

Serious or Rare Side Effects: - Coronary vasospasm: chest pain due to reduced coronary blood flow. - Myocardial infarction: rare heart attack events. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Severe hypertension: sudden high blood pressure. - Allergic reactions: rash, swelling, or anaphylaxis.

Before using Naramig, consider the following precautions: - Cardiovascular assessment: evaluate risk of coronary artery disease or uncontrolled hypertension. - Serotonergic drugs: avoid concurrent use with MAO inhibitors, SSRIs, SNRIs, or other triptans due to serotonin syndrome risk. - Hepatic/renal function: adjust use in patients with significant liver or kidney impairment. - Pregnancy and lactation: use only if potential benefit justifies potential risk; consult a healthcare professional. - Contraindications: do not use in patients with known coronary artery disease, history of stroke, or uncontrolled hypertension. - Store at ambient temperature: keep in the original package, protect from moisture and excessive heat.

Naratriptan may interact with several medications.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - SSRIs/SNRIs: heightened serotonin toxicity. - Ergot alkaloids: additive vasoconstrictive effects. - Other triptans: cumulative vasoconstriction risk. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may raise naratriptan plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine): may reduce efficacy. - Antihypertensive agents: monitor blood pressure changes. - Oral contraceptives: may slightly increase plasma concentrations.